tbuckley/cabot-search huggingface dataset:
NIMG-45. 3D SINGLE-SCAN FOR MULTI-CONTRAST-WEIGHTED MRI FOR LESION DETECTION IN PATIENTS WITH GLIOMAS
Authors: Jing Liu, Angela Jakary, Marisa Lafontaine, Yan Wang, Duan Xu, David Saloner, Nicholas Butowski, Christopher Hess, Javier Villanueva-Meyer, Susan Chang, Janine Lupo
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Multi-contrast-weighted (MCW) MRI allows derivation of T1-weighted, T2-weighted, and T2-FLAIR images and their parametric maps. Under current practice, these high-resolution 3D MR images are acquired separately with a total scan time is approximately 30 minutes. The goal of this study was to develop a novel sequence and processing strategy for MCW MRI and lesion detection of gliomas with 1mm isotropic resolution in 6 minutes, which can significantly improve clinical imaging workflow. The proposed whole brain, single-scan method enables the generation of segmented tumor regions that correspond the hyperintense lesion on T2-weighted or T2-FLAIR images (T2L). METHODS Our strategy involves using a highly accelerated 3D MRI sequence to achieve whole brain, MCW images that can be jointly segmented with modified k-means clustering. Six patients with enhancing gliomas were scanned with this sequence before the injection of gadolinium, 4 of which also received a repeat scan post-gadolinium. Our automatic segmentation of the T2L and manual definition of the contrast-enhancing lesion (CEL) was compared against manually segmented lesions drawn from conventional anatomical imaging. RESULTS Whole-brain MCW MRI was achieved with 1mm isotropic resolution in 6 mins. Grey-matter, white-matter, CSF, and the T2L could be automatically segmented with our clustering method. The resulting automatically-segmented T2L volume was not significantly different between our new sequence and clinically defined regions (average Dice Coefficient=0.81(+/-0.05); p=0.95). CONCLUSIONS Our novel, 6-minute scan and processing strategy was able to generate MCW anatomical images and automatically segment grey-matter, white-matter, and T2L volumes that were similar to manual segmentation of conventional anatomical imaging. We are currently extending the automatic segmentation to the CEL. This approach has the potential to improve clinical workflow by allowing time for therapy-specific advanced imaging and providing a noninvasive tool for monitoring tumor evolution. Validation is currently being performed in a larger cohort.
Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation
Authors: Reem Karmali, Jeremy S. Abramson, Deborah M. Stephens, Jeffrey A. Barnes, Jason Kaplan, Jane N. Winter, Shuo Ma, Juehua Gao, Adam M. Petrich, Ephraim Hochberg, Ronald W. Takvorian, Frank Kuhr, Valerie Nelson, Leo I. Gordon, Barbara Pro
Journal: Blood (2019)
QUANTIFYING THE HETEROGENEITY OF LIVER INFLAMMATION AND FIBROSIS IN PRIMARY SCLEROSING CHOLANGITIS USING THE INTERQUARTILE RANGE OF IRON-CORRECTED T1 FROM MULTI-PARAMETRIC MRI.
Authors: E Selvaraj, A Jayaswal, E M Tunnicliffe, Cobbold Jfl., J D Collier, E J Barnes, R Banerjee, M Brady, A Bailey, M Pavlides
Journal: Hepatology (2019)
Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo
Authors: Colleen Annesley, Rebecca Gardner, Ashley Wilson, Corinne Summers, Adam J. Lamble, Julie Rivers, Qian Vicky Wu, Adam Brand, Adam Johnson, Karen Spratt, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, Michael C. Jensen
Journal: Blood (2019)
Detection of actionable variants in various cancer types reveals value of whole-genome sequencing over in-silico whole-exome and hotspot panel sequencing
Authors: K.P. Ramarao-Milne, A-M Patch, K. Nones, R. Koufariotis, F. Newell, V.R. Addala, O. Kondrashova, P. Mukhopadhyay, S.H. Kazakoff, V. Lakis, O. Holmes, C. Leonard, S. Wood, C. Xu, J.V. Pearson, G. Hollway, N. Waddell
Journal: Annals of Oncology (2019)
EPID-20. TRENDS IN GLIOBLASTOMA OUTCOMES OVER TIME, GEOGRAPHIC LOCATION AND TYPE OF INTERVENTION
Authors: Lina Marenco-Hillembrand, Olindi Wijesekera, Paola Suarez-Meade, David Mampre, Christina Jackson, Kyle Ortiz, Elizabeth Lesser, Maria Hawayek, Tito Vivas-Buitrago, Alfredo Quinones-Hinojosa, Kaisorn Chaichana
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION The management of glioblastoma (GBM) has changed over time and varies based on geographic location. Despite its universally fatal prognoses, it is unclear if GBM outcomes have changed over time, if they vary by geographic location, and differ based on type of intervention. As a result, we conducted a systematic review of the literature to identify the average survival differences of GBM patients across time, between different continents, and among various treatments. METHODS The systematic review of PubMed included glioblastoma, GBM, and survival. Inclusion criteria consisted of full-text titles with human subjects, GBM/Grade IV astrocytoma, age &gt;18 years old, and with available survival data. RESULTS 9,162 articles were screened for survival data, 1728 were eligible, 405 complied with the inclusion criteria. Of the 405 studies, 179 (44.2%) were conducted in Europe, 151 (37.3%) in the Americas, 61 (15.1%) in Asia, 9 (2.2%) in Oceania, and 1 (0.2%) in Africa. Leading countries are the United States (33.1%), Germany (12.3%), and Italy (11.1%). Asia had the highest median survival (14.9 months), followed by Europe (13.2 months), and the United States (12.9 months) (P=0.003). Regarding treatment, survival was significantly higher after the introduction of the Stupp protocol (P&lt; 0.001). Post-Stupp Studies had longer survival estimates (15.3 months, range: 3.8–29.6) than Pre-Stupp Studies (12.2 months, range: 2.3–28). In the included clinical trials (182), radiation (43.4%), temozolomide (25.3%), or other chemotherapies (24.2%) were the most common interventions. Clinical trial median survival estimates were significantly higher than all other studies (P&lt; 0.017). Bevacizumab (19.3 months) and Temozolomide (15.9 months) had the longest recorded median survival estimates; while radiation (14 months), other chemotherapies, and carmustine (13.2 months) had the shortest (P=0.009). CONCLUSION This epidemiological study describes the current global state of GBM. Important differences regarding survival and treatment of patients with GBM were found.
RMC-4550, an Allosteric Inhibitor of SHP2, Displays Therapeutic Efficacy in Pre-Clinical Models of Myeloproliferative Neoplasms
Authors: Garima Pandey, Nathan Horvat, Narmin E. Amin, Afua A. Akuffo, Christelle Colin, Pearlie K. Epling-Burnette, Gary W. Reuther
Journal: Blood (2019)
From the authors
Authors: T. Verheij, J. Bont, E. Hak, A. Hoes
Journal: European Respiratory Journal (2008)

We would like to thank S. Teramoto and co-workers for the important issues they raised.While appraising their comments, it is important to make a distinction between the use of severity rules inside and outside hospital settings.Looking at the available literature, we think that the pneumonia severity index (PSI) and CURB-65 (Confusion, Urea .7 mmol?L -1 , Respiratory rate o30 breaths?min -1 , Blood pressure (systolic value ,90 mmHg or diastolic value f60 mmHg)) are both valid and useful in hospital settings.However, it is an interesting suggestion to improve CURB-65 by introducing more detailed age groups in the score.In primary care, PSI and CURB-65 are less useful for various reasons.Regarding the predictive value of age, the results of our study [1] showed that age .80yrs was a better predictor of outcome than age categories between 65-80 yrs.Probably as there are a lot of healthy individuals aged 65-80 yrs in primary care who have a low risk for poor outcome.
UM171 Regulates the Hematopoietic Differentiation of Human Acquired Aplastic Anemia-Derived Induced Pluripotent Stem Cells
Authors: Tellechea Maria Florencia, Flavia S. Donaires, Tiago C. Silva, Lilian F. Moreira, Yordanka Armenteros, Rodrigo T. Calado
Journal: Blood (2019)
Proposal of a "2-Step-Algorithm" for the Screening of Myeloproliferative Neoplasms in Individuals with Erythrocytosis
Authors: Miguel Piris-Villaespesa, Gloria Muñoz-Martin, Claudia Stock, Adolfo Saez-Martin, Ricardo Sanchez, Javier Zamora, Francisco Javier del Castillo, Jesus Villarrubia, Javier Lopez Jimenez, Joaquin Martinez-Lopez, Valentin Garcia Gutierrez
Journal: Blood (2019)
TB screening and anti-TNFα treatment
Authors: D J Dhasmana, J Nash, J C Bradley, D Creer
Journal: Thorax (2006)

We read with interest the letter by Provenzano et al 1 on TB screening and anti-TNFα treatment and wish to comment on this highly topical subject.

Latent TB infection (LTBI) was diagnosed in 24.6% of the 69 rheumatological patients undergoing evaluation for anti-TNFα treatment (n = 17), six of whom received anti-TNFα treatment and TB chemoprophylaxis. The ethnicity and place of birth was not given, which may have had some bearing on this apparently high incidence of LTBI. Previous BCG vaccination was not reported in the cohort, particularly in those (8.7%) with a positive Mantoux test, which could give rise to false positive results. Before Mantoux testing steroids were stopped (for 1 week) but no comment is made regarding other immunosuppressive treatments which might interfere with the accuracy of tuberculin skin testing2 and would account for the poor sensitivity of the Mantoux test in this cohort (sensitivity 35%). It is also unclear whether the two patients with a previous history of TB had received appropriate treatment at the time of initial diagnosis or whether they were subsequently included in the six patients who received chemoprophylaxis. Recent BTS guidelines recommend that patients who have previously been adequately treated should be monitored rather than receive …
Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidentical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Incidence, Distribution and Response to Therapy
Authors: Melhem Solh, Xu Zhang, Asad Bashey, Lawrence E Morris, H. Kent Holland, Scott R. Solomon
Journal: Blood (2019)
A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy
Authors: Sunita Dwivedy Nasta, Mitchell E. Hughes, Esin C. Namoglu, Daniel J. Landsburg, Elise A. Chong, Stefan K. Barta, Noelle V. Frey, James N. Gerson, Amit Maity, John Plastaras, David L. Porter, Marco Ruella, Jakub Svoboda, Hatcher J. Ballard, Stephen J. Schuster
Journal: Blood (2019)
HOUT-01. ALOPECIA SYMPTOM IMPACT SCALE (ASIS): MEASURING THE SYMPTOMS OF ALOPECIA AND THEIR IMPACT IN PATIENTS WITH PRIMARY BRAIN TUMORS
Authors: Tito Mendoza, Lindsay Rowe, Elizabeth Vera, Alvina Acquaye, Mark Gilbert, Terri Armstrong
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Alopecia manifests in many cancer patients receiving therapy. These patients may experience similar physical symptoms and impairment as patients with autoimmune alopecia areata. The Alopecia Areata Symptom Impact Scale (AASIS) was originally validated for patients with autoimmune disorder. However, the validity and reliability of the AASIS among primary brain tumor (PBT) patients has not been evaluated. METHODS A cross sectional survey of 100 PBT patients was conducted as part of an IRB approved prospective protocol using structured questionnaires and open-ended responses. Participants completed the AASIS to measure symptoms of alopecia areata and their impact on daily functioning along with the Body Image Scale (BIS) to assess the prevalence of body image disturbance. Analyses included factor analysis to determine the number and nature of underlying constructs, Cronbach’s alphas to assess reliability, and correlational analysis to establish concurrent validity. RESULTS Patients’ median age was 48(range 23– 74), and 56% were male. Glioblastoma was most common (32%); low grade tumors (I and II) were 30% of diagnoses. The median time from initial diagnosis was 5 years (range 0–22), and 64% of patients had a KPS of 90–100. An item from the AASIS, ‘body hair or eyelashes loss’, was deemed to be irrelevant, rated low by PBT patients and was removed. Factor analysis revealed 3 underlying constructs: physical (e.g. itchy skin, scalp hair loss), affective (e.g. feeling anxious, feeling sad) symptoms, and impact of alopecia (e.g. work, quality of life) with Cronbach’s alphas of 0.78, 0.89 and 0.96, respectively. The BIS had the highest correlation with the affective symptom subscale (0.58, p&lt; .001). CONCLUSION Our results demonstrate the desired reliability and validity for use in studies examining alopecia and its impact in PBT patients. Dropping the term ‘areata’, the modified tool is now ASIS, and can be implemented in future studies.
Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG)
Authors: Frank G. Rücker, Mridul Agrawal, Andrea Corbacioglu, Daniela Weber, Silke Kapp-Schwoerer, Verena I. Gaidzik, Nikolaus Jahn, Thomas Schroeder, Mohammad Wattad, Michael Lübbert, Elisabeth Koller, Thomas Kindler, Katharina Götze, Mark Ringhoffer, Jörg Westermann, Walter Fiedler, Heinz A. Horst, Richard Greil, Roland Schroers, Karin Mayer, Thomas Heinicke, Jürgen Krauter, Richard F. Schlenk, Felicitas Thol, Michael Heuser, Arnold Ganser, Lars Bullinger, Peter Paschka, Hartmut Döhner, Konstanze Döhner
Journal: Blood (2019)
Asparaginase-Associated Pancreatitis in ALL: Results from the NOPHO ALL2008 Treatment of Patients 1-45 Years
Authors: Cecilie Utke Rank, Benjamin Ole Wolthers, Kathrine Grell, Birgitte Klug Albertsen, Thomas Leth Frandsen, Ulrik Malthe Overgaard, Nina Toft, Ove Juul Nielsen, Peder Skov Wehner, Arja Harila-Saari, Mats Heyman, Jonas Abrahamsson, Ulrika Norén-Nyström, Beata Tomaszewska-Toporska, Bendik Lund, Kirsten Brunsvig Jarvis, Petter Quist-Paulsen, Goda Elizabeta Vaitkeviciene, Laimonas Griškevičius, Mervi Taskinen, Ulla Wartiovaara-Kautto, Kristi Lepik, Mari Punab, Ólafur Gísli Jónsson, Kjeld Schmiegelow
Journal: Blood (2019)
Association between particulate matter air pollution and lung cancer
Authors: Zhenyu Zhang, Dawei Zhu, Bin Cui, Ruoxi Ding, Xuefeng Shi, Ping He
Journal: Thorax (2019)

Long-term exposure to particulate matter 2.5 μm (PM2.5) air pollution is associated with an increased risk of lung cancer. However, the evidence is limited in low-income and middle-income countries. We estimated the association between the incidence of lung cancer and PM2.5 air pollution exposure in the Urban Employee Basic Medical Insurance (UEBMI) beneficiaries in China. A total of 16 483 new lung cancer cases diagnosed from 12 966 137 UEBMI beneficiaries from 36 cities between 2013 and 2016. The relative risk for lung cancer associated with a 10 µg/m3 increase in 3-year PM2.5 exposure was 1.12 (95% CI 1.00 to 1.26). The population attributable risk estimated for a reduction in PM2.5 concentration to 35 µg/m3 corresponded to a decrease of 14% in cases of lung cancer. Reducing PM2.5 air pollution has a significant public health benefit.
DDRE-30. HIGH-THROUGHPUT DRUG SCREENING OF FDA-APPROVED ANTINEOPLASTIC DRUGS FOR THE TREATMENT OF AGGRESSIVE MENINGIOMAS
Authors: Gerhard Jungwirth, Tao Yu, Fang Liu, Rolf Warta, Andreas Unterberg, Christel Herold-Mende
Journal: Neuro-Oncology (2020)

Abstract The management of aggressive meningiomas remains challenging due to limited treatment options besides surgical removal and radiotherapy. High recurrence rates and lack of effective chemotherapies may be reasons for the unfavorable prognosis of these patients. Consequently, there is an urgent need to identify effective therapeutic agents. For this purpose, we performed a high-throughput screening utilizing a drug library consisting of 147 FDA-approved antineoplastic drugs on the anaplastic meningioma cell line NCH93 using CellTiter-Glo (Promega). Based on the lowest IC50, the top 5 drugs were selected including Bortezomib, Carfilzomib, Omacetaxine, Ixabepilone, and Romidepsin. Validation of candidate compounds was performed in Ben-Men-1 (grade I), NCH93 (grade III), and IOMM-Lee cells (grade III) using crystal violet assay. Dose-curve analysis revealed IC50 values in the lower nanomolar range for all compounds and all cell lines (0.2 – 16.2 nM). To further substantiate our findings, cell proliferation assessed by manual counting was significantly reduced by up to 90% by each candidate drug at 10xIC50 after 48 h (P &amp;lt; 0.001). Furthermore, cell migration was inhibited up to 60% by all candidate drugs at the respective IC50 (P &amp;lt; 0.05). However, colony formation was only significantly reduced by Bortezomib and Carfilzomib (P &amp;lt; 0.001). The impact of the drugs on cell cycle and apoptosis was analyzed by flow cytometry using Annexin V/PI staining. All candidate drugs induced cell cycle arrest at G0/G1 or G2/M phase (P &amp;lt; 0.001) and subsequently induced apoptosis. Among them, Bortezomib exhibited the most pronounced effect by up to 80% of apoptotic cells (P &amp;lt; 0.001). In summary, by utilizing a high-throughput drug screening we were able to identify Bortezomib, Carfilzomib, Omacetaxine, Ixabepilone, and Romidepsin as potent antineoplastic agents for the treatment of aggressive meningiomas.
Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Authors: Guillaume Richard-Carpentier, Hagop M. Kantarjian, Nicholas J. Short, Farhad Ravandi, Alessandra Ferrajoli, Heather M Schroeder, Guillermo Garcia-Manero, Guillermo Montalban Bravo, Jorge E. Cortes, Monica Kwari, Christopher Loiselle, Rebecca Garris, Nicole Volter, Nitin Jain, Marina Y Konopleva, Koichi Takahashi, Koji Sasaki, William G. Wierda, Elias Jabbour
Journal: Blood (2019)
Persistent Red Blood Cell (RBC) Transfusion Is Associated with Increased Mortality Risk in Transfusion-Dependent (TD) Patients with Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS+)
Authors: Rena Buckstein, Nancy Zhu, Mary-Margaret Keating, Brian Leber, Lisa Chodirker, Mitchell Sabloff, Grace Cristou, Heather A. Leitch, Eve St. Hilaire, Nicholas Finn, Karen W.L. Yee, Mohamed Elemary, Versha Banerji, Martha Lenis, Aksharh Kirubananthaan, Fei Fei Liu, Derek Tang, Chris Westcott, Vicky Wei-Hsuen Huang, Di Wang, Chris Cameron, Jessica Morison, Paul Spin, Alexandre Mamedov
Journal: Blood (2019)
PATH-06. A TARGETED NGS-BASED OVERALL SOLUTION TO SUPPORT DIAGNOSTICS AND THERAPY PREDICTION IN NEUROONCOLOGY: CONSIDERATIONS FOR A FLEXIBLE AND COST-EFFICIENT PLATFORM CHOICE AND PANEL DESIGN
Authors: Markus Riemenschneider, Andras Rudolf, Peter Hau, Tobias Pukrop, Oliver Kölbl, Selim Corbacioglu, Alexander Brawanski, Martin Proescholdt, Julia Lorenz
Journal: Neuro-Oncology (2019)

Abstract Continuous updates add novel molecular markers to the WHO classification of CNS tumors. Additionally, molecularly informed trials may provide the basis for the introduction of additional predictive biomarkers. All these developments will prospectively require molecular testing to a yet unknown extent and still pose challenges to many neuropathology labs. Some of the relevant alterations (e.g. C11orf95-RELA) are hard to assess or complex subclassifications (e.g. for medulloblastomas) are required. Some labs rely on a two-tiered approach: i) methylation arrays for tumor classification and ii) targeted NGS panel sequencing for identifying actionable mutations. However, high initial investment and annual costs for running two platforms in parallel hinder a fast expansion of the new techniques in the breadth of neuropathology. We decided to focus on the sole use of the relatively cost-efficient Mini-Seq NGS platform (Illumina). First, we designed a DNA panel (FFPE, HaloPlex, Agilent; no Covaris required) that is suited for detection of DNA mutations, copy number alterations and chromosomal alterations (459 kbp, 58 genes, 4082 SNPs, 98.83% coverage). We successfully used this platform to support tumor classification in astrocytomas, oligodendrogliomas, meningiomas and medulloblastomas and identified actionable targets of clinical use. We then designed a RNA panel (FFPE, Sure Select, Agilent) that detects gene fusions and covers a broad range of alterations particularly relevant to pediatric tumors (e.g. pediatric glioblastomas, ependymomas, CNS PNETs) (148 kbp, coding sequence of 31 genes, 99.88% coverage). With these two panels we cover the most relevant molecular alterations in the field of neurooncology. The cost-efficient and flexible single platform approach enables state-of-the-art molecular diagnostics in virtually every neuropathology lab in a quality-controlled manner. Functionality is guaranteed for future revisions of the WHO classification as novel biomarkers can be easily included in an adapted panel design.
Correction: Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma
Authors: Mark Yarchoan, Parul Agarwal, Augusto Villanueva, Shuyun Rao, Laura Dawson, Thomas Karasic, Joseph Llovet, Richard Finn, John Groopman, Hashem El-Serag, Satdarshan Monga, Xin Wei Wang, Michael Karin, Robert Schwartz, Kenneth Tanabe, Lewis Roberts, Preethi Gunaratne, Allan Tsung, Kimberly Brown, Theodore Lawrence, Riad Salem, Amit Singal, Amy Kim, Atoosa Rabiee, Linda Resar, Jeffrey Meyer, Yujin Hoshida, Aiwu Ruth He, Kalpana Ghoshal, Patrick Ryan, Elizabeth Jaffee, Chandan Guha, Lopa Mishra, Norman Coleman, Mansoor Ahmed
Journal: Cancer Research (2019)

In the original version of [this article][1] ([1][2]), authors Thomas Karasic and Jeffrey Meyer are mistakenly omitted from the author list. This error has been corrected in the latest online HTML and PDF versions of the article and the author contributions and disclosures have been updated as
Role of Disease Mechanism in Hematopoietic Cell Transplantation Outcomes for Hemophagocytic Lymphohistiocytosis
Authors: Aleksandra S. Dain, Michelle L. Hermiston, Kristin A. Shimano, Sandhya Kharbanda, Alexis Melton, Jasmeen Dara, James N Huang, Christopher C. Dvorak
Journal: Blood (2019)